{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0035312_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"045-427-854-621-421","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11782,"type":"PATENT","title":"Maastricht University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":578,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8416,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: Maastricht Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 533
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
Search Applicants and Owners separately: Maastricht Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 533
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
(a) producing a cDNA library from tumor endothelial cells (TEC), producing a cDNA library from normal endothelial cells (NEC), and producing a cDNA library from active endothelial cells (AEC),\n
(b) performing suppression subtractive hybridization (SSH) of TEC subtracted with NEC, and\n
(c) performing SSH of TEC subtracted with AEC,\n
thereby identifying the cDNAs that are overexpressed in TEC relative to NEC or AEC as TAGs, or\n
(c′) performing SSH of AEC subtracted with TEC, thereby identifying the cDNAs that are underexpressed in TEC relative to NEC or AEC as TAGs,\nwherein\n
(i) the endothelial cells for producing said cDNA libraries are pooled from at least two different patients,\n
(ii) the endothelial cells for producing said cDNA libraries are isolated to at least 90% purity, and\n
(iii) the cDNA libraries maintain the original representation of transcripts."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said tissue with enhanced angiogenesis (AEC) is placental endothelial cells (PLEC)."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said endothelial cells are isolated to at least 95% purity, and preferably to 97% purity."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said endothelial cells are pooled from at least 5 different patients."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["An isolated nucleic acid comprising a member selected from a group of nucleic acids identifiable as tumor angiogenesis associated gene (TAG) according to the method of claim 6, said group consisting of:\n
(a) a nucleic acid comprising a DNA sequence as given in SEQ ID NO: 1 , 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, or a part thereof, or the complement thereof,\n
(b) a nucleic acid comprising the RNA sequences corresponding to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, or a part thereof, or the complement thereof,\n
(c) a nucleic acid specifically hybridizing to the nucleotide sequence as defined in (a) or (b),\n
(d) a nucleic acid comprising a nucleotide sequence, which is at least 65% identical to the sequence defined in (a),\n
(e) a nucleic acid encoding a protein with an amino acid sequence, which is at least 65% identical to the amino acid sequence as given in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or apart thereof,\n
(f) a nucleic acid encoding a protein comprising the amino acid sequence as given in any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or a part thereof,\n
(g) a nucleic acid which is degenerated as a result of the genetic code to a nucleotide sequence of a nucleic acid as given in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, or a part thereof or as defined in (a) to (f),\n
(h) a nucleic acid which is diverging due to the differences in codon usage between the organisms to a nucleotide sequence encoding a protein as given in SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34 or as defined in (a) to (g),\n
(i) a nucleic acid which is diverging due to the differences between alleles encoding a protein as given in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or as defined in (a) to (h),\n
j) a nucleic acid encoding an immunologically active and/or functional fragment of a protein encoded by a DNA sequence as given in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33,\n
(k) a nucleic acid encoding a gene family member of the nucleic acid as given in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33,\n
(l) a nucleic acid encoding a protein as defined in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or a nucleic acid as defined in any one of (a) to (k) characterized in that said sequence is DNA, cDNA, genomic DNA or synthetic DNA, and\n
(m) a nucleic acid molecule of at least 12 nucleotides in length specifically hybridizing with or amplifying a nucleic acid according to (a) to (l) above."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["An isolated polypeptide encodable by a nucleic acid according to claim 11, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The polypeptide according to claim 14, comprising an amino acid sequence as given in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["An antibody specifically recognizing a polypeptide according to claim 14 or a specific epitope of said polypeptide."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A vector comprising a nucleic acid according to claim 11."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The vector according to claim 17, wherein said vector is an expression vector"],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The expression vector according to claim 18, wherein the nucleic acid is operably linked to one or more control sequences allowing the expression of said sequence in prokaryotic and/or eukaryotic host cells."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A host cell comprising an integrated or episomal copy of a nucleic acid according to claim 11."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The host cell according to claim 20, wherein said host cell is a yeast, bacterial, insect, fungal, plant, fish, avian, reptilian or mammalian cell."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A method of identifying an agent that modulates proliferative diseases or disorders, said method comprising:\n
(a) contacting a cell line (over)expressing any of SEQ ID NO:s 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33 in the presence and absence of a candidate modulator under conditions permitting the interaction of said candidate modulator with said cell; and\n
(b) measuring the expression of said SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33,\nwherein a modulation in expression of said SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, in the presence of said candidate modulator, relative to the expression in the absence of said candidate modulator identifies said candidate modulator as an agent that modulates proliferative diseases or disorders."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A method of identifying an agent that modulates proliferative diseases or disorders, said method comprising:\n
(a) contacting a cell line (over)expressing any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34 in the presence and absence of a candidate modulator under conditions permitting the interaction of said candidate modulator with said cell; and\n
(b) measuring the expression of said SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, wherein a modulation in expression of said SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, in the presence of said candidate modulator, relative to the expression in the absence of said candidate modulator identifies said candidate modulator as an agent that modulates proliferative diseases or disorders."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["A method for screening agents for preventing, treating or alleviating proliferative diseases or disorders, comprising the steps of:\n
(a) contacting the agent to be screened with a nucleic acid according to claim 11, or with an isolated polypeptide encodable by a nucleic acid according to claim 11, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof, and,\n
(b) determining whether said agent affects the expression activity of said nucleic acid or said polypeptide."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A method for screening agents that interact with the polypeptide according to claim 14 comprising:\n
(a) combining the polypeptide according to claim 14 with an agent, to form a complex, and,\n
(b) detecting the formation of a complex, wherein the ability of the agent to interact with said polypeptide, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof, is indicated by the presence of the agent in the complex."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["A method to identify candidate drugs for treating a pathological condition or a susceptibility to a pathological condition, comprising:\n
contacting a test agent with cells which express one or more genes selected from the group consisting of SEQ ID NO:s 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 and 33, including parts thereof,\n
determining the amount of expression of said one or more genes by hybridization of mRNA of said cells or cDNA or cRNA copied from said mRNA to a nucleic acid probe which is complementary to an mRNA of said one or more genes;\n
identifying a test agent as a candidate drug for treating a pathological condition or a susceptibility to a pathological condition if it modulates the expression of said one or more genes."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 28, wherein said pathological condition is a tumor, and wherein said test agent is identified as a candidate drug for treating said tumor if it decreases expression of said one or more genes."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 28, wherein said a pathological condition is impaired wound healing, and wherein said test agent is identified as a candidate drug for treating said impaired wound healing if it increases expression of said one or more genes."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["A method to identify candidate drugs for treating a pathological condition or a susceptibility to a pathological condition, comprising: contacting a test agent with cells which express one or more proteins selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof; determining the amount of said one or more of said proteins in said cells; identifying a test agent as a candidate drug for treating a pathological condition or a susceptibility to a pathological condition if it modulates the amount of one or more of said proteins in said cells."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 31, wherein said pathological condition is a tumor, and wherein said test agent is identified as a candidate drug for treating said tumor if it decreases the amount of one or more of said proteins in said cells."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 31, wherein said pathological condition is impaired wound healing, and wherein said test agent is identified as a candidate drug for treating said impaired wound healing if it increases the amount of one or more of said proteins in said cells."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["A method for identifying candidate drugs for treating a pathological condition or a susceptibility to a pathological condition, such as tumors or wounds, comprising:\n
contacting a test agent with cells which express one or more proteins selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof;\n
determining activity of said one or more proteins in said cells;\n
identifying a test agent as a candidate drug for treating a pathological condition or a susceptibility to a pathological condition if it modulates the activity of said one or more proteins in said cells."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 34, wherein said pathological condition is a tumor, and wherein said test agent is identified as a candidate drug for treating said tumor if it decreases the activity of one or more of said proteins in said cells."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 34, wherein said pathological condition is impaired wound healing, and wherein said test agent is identified as a candidate drug for treating said impaired wound healing if it increases the activity of one or more of said proteins in said cells."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method according to any of claims 28, 31 or 34, wherein the cells are endothelial cells or recombinant host cells which are transfected with an expression construct which encodes said one or more proteins."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["A method to identify candidate drugs for treating patients having a pathological condition or a susceptibility to a pathological condition, such as bearing tumors or for treating wounds, comprising:\n
contacting a test agent with recombinant host cells which are transfected with an expression construct which encodes one or more proteins selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof;\n
determining the amount of proliferation of said cells;\n
identifying a test agent as a candidate drug for treating patients having a pathological condition or a susceptibility to a pathological condition if it modulates the proliferation of said cells."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 39, wherein said pathological condition is a tumor, and wherein said test agent is identified as a candidate drug for treating said tumor if it inhibits proliferation of said cells."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 39, wherein said pathological condition is impaired wound healing, and wherein said test agent is identified as a candidate drug for treating said impaired wound healing if it stimulates proliferation of said cells."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising the steps of:\n
(a) determining the over- or underexpression of a nucleic acid according to claim 11 or isolated polypeptide encodable by a nucleic acid according to claim 11, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof, in a biological sample relative to the expression in a control sample, and,\n
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the over- or underexpression of said nucleic acid or said polypeptide in said biological sample relative to the expression in a control sample."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing a pathological condition or a susceptibility to a pathological condition, said method comprising:\n
(a) contacting a tissue sample with an antibody specific for any of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or apart thereof;\n
(b) detecting binding of said antibody to said tissue sample;\n
(c) comparing the binding detected in step (b) with a standard, wherein a difference in binding relative to the standard is diagnostic of a pathological condition or a susceptibility to a pathological condition."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 45, wherein said detecting is performed by FACS."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing a pathological condition or a susceptibility to a pathological condition, said method comprising:\n
(a) contacting a tissue sample with a probe specific for any of SEQ ID NO:s 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, or a part thereof;\n
(b) detecting binding of said probe to said tissue sample;\n
(c) comparing the binding detected in step (b) with a standard, wherein a difference in binding relative to the standard is diagnostic of a pathological condition or a susceptibility to a pathological condition."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["A method for diagnosing a pathological condition or a susceptibility to a pathological condition, comprising the steps of:\n
(a) detecting an expression product of at least one gene in a first tissue sample suspected of a pathology, wherein said at least one gene is selected from the group consisting of SEQ ID NO:s 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 and 33, including parts thereof; and\n
(b) comparing expression of the expression product of at least one gene in the first tissue sample with expression of the expression product of the at least one gene in a second tissue sample which is normal, wherein a difference in expression of the expression product of the at least one gene in the first tissue sample relative to the second tissue sample identifies the first tissue sample as likely to be pathological or susceptible to a pathological condition."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 51, wherein the difference in expression, the increased expression or the decreased expression of the at least one gene in the first tissue sample relative to the second tissue sample is at least 2-fold, and preferably, 5-fold or 10-fold."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 51, wherein the expression product is RNA."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["A method for diagnosing a pathological condition or a susceptibility to a pathological condition, comprising the steps of:\n
(a) detecting an expression product of at least one gene in a first tissue sample suspected of pathological wherein said expression product of at least one gene is selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof; and\n
(b) comparing expression of the expression product of at least one gene in the first tissue sample with expression of the expression product of the at least one gene in a second tissue sample which is normal, wherein a difference in expression of the expression product of the at least one gene in the first tissue sample relative to the second tissue sample identifies the first tissue sample as likely to be pathological or susceptible to a pathology."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claims 51 or 56, wherein the first and second tissue samples are from a human."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 59, wherein the first and second tissue samples are from the same human."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating or alleviating proliferative diseases or disorders, comprising the use of an agent which allows to interfere with the expression of a nucleic acid according to claim 11 or an isolated polypeptide encodable by a nucleic acid according to claim 11, or a variant or a derivative thereof, or an immunologically active and/or functional fragment thereof."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 63, wherein said agent is an antisense molecule or an siRNA directed specifically against any of SEQ ID NO:s 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31 or 33, or a part thereof, or an antibody directed specifically against any of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or a part thereof."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 63, wherein said proliferative disorders are vascularized tumors possibly comprising enhanced angiogenesis and/or tumor endothelial cells."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating a vascularized tumor, comprising the step of: contacting cells of the vascularized tumor with an antibody, wherein the antibody specifically binds to an extracellular epitope of a protein selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof; whereby immune destruction of cells of the vascularized tumor is triggered."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["A method for regulating cell proliferation, said method comprising introduction of a nucleic acid according to claim 11, or an expression vector comprising the nucleic acid according to claim 11 in a desired target cell."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":72,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":73,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":74,"annotation":false,"claim":true,"title":false},{"lines":["A kit for the diagnosis of a pathological condition disorders in a patient comprising a nucleic acid according to claim 11, or an antibody specifically recognizing a polypeptide encodable by the nucleic acid of claim 11."],"number":75,"annotation":false,"claim":true,"title":false},{"lines":["The kit according to claim 75, wherein said pathological condition is a proliferative disease or disorder or impaired wound healing."],"number":76,"annotation":false,"claim":true,"title":false},{"lines":["A transgenic non-human animal comprising one or more copies of a nucleic acid according to claim 11 stably integrated in the genome, or an animal comprising regulatory elements that modulate the expression of a nucleic acid according to claim 11."],"number":77,"annotation":false,"claim":true,"title":false},{"lines":["A knock-out non-human animal comprising a deletion of one or two alleles encoding a nucleic acid according to claim 11, or a animal comprising a targeted mutation in the genomic region, including regulatory sequences, comprising any of the nucleic acid sequences according to claim 11."],"number":78,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":79,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":80,"annotation":false,"claim":true,"title":false},{"lines":["A method for producing a polypeptide comprising culturing a host cell according to claim 20 under conditions allowing the expression of said polypeptide."],"number":81,"annotation":false,"claim":true,"title":false},{"lines":["A method for identification of a ligand involved in endothelial cell regulation, comprising:\n
(a) contacting an isolated and purified human protein selected from the group consisting of SEQ ID NO:s 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 and 34, including parts thereof, with a test agent and a molecule comprising an antibody variable region which specifically binds to a domain of said SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32 or 34, or a part thereof; and\n
(b) determining the amount of binding of the molecule comprising an antibody variable region to the human protein; whereby a test agent which diminishes the binding of the molecule comprising an antibody variable region to the human protein is identified as a ligand involved in endothelial cell regulation."],"number":82,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 82 further comprising: contacting the test compound with endothelial cells and determining if the test compound inhibits growth of said cells."],"number":83,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 83, wherein the endothelial cells are in culture."],"number":84,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 83, wherein the endothelial cells are in a mammal."],"number":85,"annotation":false,"claim":true,"title":false},{"lines":["A method for selecting and/or staining endothelial cells comprising a step of using a combination of anti-CD31 and anti-CD34 antibodies."],"number":86,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}